Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction

Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03169582

Enrollment

Registered

2017-05-30

Start date

2016-04-01

Completion date

2018-06-01

Last updated

2017-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Brief summary

The main goal of this study is to compare the use of Avanafil versus Sildenafil in spinal cord injury erectile dysfunction. The study has the characteristics of a non- inferiority, randomized, crossover, open clinical trial. The principal variable is the IIEF-EF (Erectile Function Domain questionnaire of the International Index of Erectile Function IIEF). This is an interventional study

Interventions

DRUGAvanafil

Drug administration (Avanafil)

DRUGSildenafil

Drug administration (Sildenafil)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

non- inferiority, randomized, crossover, open clinical trial

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Spinal cord injury * Erectile dysfunction * No Medical Contraindication to use Avanafil and/or Sildenafil * Able to provide informed consent * Able to complete questionnaires

Exclusion criteria

* Medical Contraindication to use Avanafil and/or Sildenafil * No spinal cord injury * Congenital spinal cord injury * Not able to provide informed consent * Not able to complete questionnaires

Design outcomes

Primary

Measure	Time frame	Description
IIEF-EF	2 years	Erectile Function Domain questionnaire of the International Index of Erectile Function.

Secondary

Measure	Time frame	Description
SLQQ-Part II	2 years	Sexual life quality Questionnaire
GAQ	2 years	Global Impression of efficacy

Countries

Spain

Contacts

Primary ContactEduardo Vargas-Baquero, MD

edua33@hotmail.com+34925247700

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026